BMS Collaborates with Aveo to Evaluate Opdivo (nivolumab) + Fotivda (tivozanib) in P-III Study for Relapsed Renal Cell Carcinoma

 BMS Collaborates with Aveo to Evaluate Opdivo (nivolumab) + Fotivda (tivozanib) in P-III Study for Relapsed Renal Cell Carcinoma

BMS Collaborates with Aveo to Evaluate Opdivo (nivolumab) + Fotivda (tivozanib) in P-III Study for Relapsed Renal Cell Carcinoma

Shots:

  • The P-III TiNivo-2 study involves assessing Fotivda (1.34 mg/qd for 21days followed by 7days off treatment) + Opdivo (480 mg, q4w) in ~326 patients in a ratio (1:1) with advanced r/r metastatic RCC following prior immunotherapy exposure
  • The study plans to enroll patients across the US, EU, and Latin America. The 1EP of the study is PFS while the 2EPs include OS, ORR, DoR & safety
  • Additionally, BMS will provide Opdivo clinical drug supply for the study and AVEO will serve as the study sponsor and will be responsible for costs associated with the trial execution

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Aveo Oncology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post